Researchers confirmed the long-term safety profile of ozanimod for the treatment of moderate to severe UC or RMS.

Mental health comorbidities are more prevalent among transgender and gender nonconforming adults with IBD than the general and IBD US populations.

No significant difference in the risk for MACE was observed between patients with IBD receiving JAK vs TNF inhibitors.

Ileosigmoid fistulas in Crohn disease are surgically managed in varying ways, which suggests a need for standardized guidelines.

Risankizumab for Crohn disease taken over a long-term extension results in clinically meaningful sustained HRQOL improvements.